The isocitrate dehydrogenase 1 (IDH1) mutation was reported to be a biomarker in the prediction of clinical outcomes for patients with GBM, and patients with IDH1 mutations exhibit better outcome than those with wild-type IDH1 in gliomas. This evidence concerns the gene IDH1 and glioma.